Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

Knowledge of oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells while sparing normal cells. Lenalidomide is an active agent in the activated B-cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), but its mechanism of action is un...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Yang, Yibin, Shaffer, Arthur L., Emre, N.C. Tolga, Ceribelli, Michele, Zhang, Meili, Wright, George, Xiao, Wenming, Powell, John, Platig, John, Kohlhammer, Holger, Young, Ryan M., Zhao, Hong, Yang, Yandan, Xu, Weihong, Buggy, Joseph J., Balasubramanian, Sriram, Mathews, Lesley A., Shinn, Paul, Guha, Rajarshi, Ferrer, Marc, Thomas, Craig, Waldmann, Thomas A., Staudt, Louis M.
Формат: Artigo
Язык:Inglês
Опубликовано: 2012
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4059833/
https://ncbi.nlm.nih.gov/pubmed/22698399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2012.05.024
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы